GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » I-MAB (NAS:IMAB) » Definitions » Liabilities-to-Assets

I-MAB (IMAB) Liabilities-to-Assets : 0.34 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is I-MAB Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. I-MAB's Total Liabilities for the quarter that ended in Dec. 2023 was $125.32 Mil. I-MAB's Total Assets for the quarter that ended in Dec. 2023 was $365.95 Mil. Therefore, I-MAB's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2023 was 0.34.


I-MAB Liabilities-to-Assets Historical Data

The historical data trend for I-MAB's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

I-MAB Liabilities-to-Assets Chart

I-MAB Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Liabilities-to-Assets
Get a 7-Day Free Trial 2.17 0.11 0.19 0.29 0.34

I-MAB Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.19 0.20 0.29 0.30 0.34

Competitive Comparison of I-MAB's Liabilities-to-Assets

For the Biotechnology subindustry, I-MAB's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


I-MAB's Liabilities-to-Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, I-MAB's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where I-MAB's Liabilities-to-Assets falls into.



I-MAB Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

I-MAB's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Liabilities-to-Assets (A: Dec. 2023 )=Total Liabilities/Total Assets
=125.32/365.952
=0.34

I-MAB's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2023 is calculated as

Liabilities-to-Assets (Q: Dec. 2023 )=Total Liabilities/Total Assets
=125.32/365.952
=0.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


I-MAB  (NAS:IMAB) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


I-MAB Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of I-MAB's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


I-MAB (IMAB) Business Description

Industry
Traded in Other Exchanges
Address
555 West Haiyang Road, 55th Floor, New Bund Center, Pudong District, Shanghai, CHN, 200124
I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will likely be eftansomatropin, a long-acting growth hormone that has a large market in China among pediatric patients with short stature, which we estimate will launch in 2024 or 2025. Other core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor in phase 2 trials; uliledlimab, a potential best-in-class CD73 inhibitor in phase 2 trials; and felzartamab for the Chinese market, a CD38 inhibitor for multiple myeloma, which could have a phase 3 data readout in 2023.